These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 37154806)

  • 21. Search for potentially biased epidermal growth factor receptor (EGFR) inhibitors through pharmacophore modelling, molecular docking, and molecular dynamics (MD) simulation approaches.
    Jethwa M; Gangopadhyay A; Saha A
    J Biomol Struct Dyn; 2023 Mar; 41(5):1681-1689. PubMed ID: 35014597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacotherapeutics and Molecular Mechanism of Phytochemicals in Alleviating Hormone-Responsive Breast Cancer.
    Rampogu S; Park C; Ravinder D; Son M; Baek A; Zeb A; Bavi R; Kumar R; Lee G; Parate S; Pawar SC; Park Y; Park SJ; Lee KW
    Oxid Med Cell Longev; 2019; 2019():5189490. PubMed ID: 31089409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
    Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of the allosteric inhibitor from actinomyces metabolites to target EGFR
    Saini R; Kumari S; Bhatnagar A; Singh A; Mishra A
    Sci Rep; 2023 Jun; 13(1):8885. PubMed ID: 37264083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identifying novel and potent inhibitors of EGFR protein for the drug development against the breast cancer.
    Siddiqui AJ; Jahan S; Patel M; Abdelgadir A; Alturaiki W; Bardakci F; Sachidanandan M; Badraoui R; Snoussi M; Adnan M
    J Biomol Struct Dyn; 2023; 41(23):14460-14472. PubMed ID: 36826428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computational Exploration of Fluorocyclopentenyl-purines and-pyrimidines Derivatives as Potential Inhibitors of Epidermal Growth Factor Receptor (EGFR) for the Treatment of Breast Cancer.
    Abida Ejaz S; Sajjad Bilal M; Aziz M; Wani TA; Zargar S; Fayyaz A; Hassan S; Ahmed A; Al Kahtani HM; Siddique F
    Chem Biodivers; 2023 Dec; 20(12):e202301190. PubMed ID: 37963090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.
    Sangande F; Julianti E; Tjahjono DH
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096664
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Parvizpour S; Elengoe A; Alizadeh E; Razmara J; Shamsir MS
    J Biomol Struct Dyn; 2023 Nov; 41(19):10037-10050. PubMed ID: 36451602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential target identification for breast cancer and screening of small molecule inhibitors: A bioinformatics approach.
    Agarwal S; Kashaw SK
    J Biomol Struct Dyn; 2021 Apr; 39(6):1975-1989. PubMed ID: 32186248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of potential HER2 inhibitors from
    Balogun TA; Iqbal MN; Saibu OA; Akintubosun MO; Lateef OM; Nneka UC; Abdullateef OT; Omoboyowa DA
    J Biomol Struct Dyn; 2022; 40(23):12772-12784. PubMed ID: 34514973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploring the potential of phytochemicals as inhibitors of 3'-phosphoadenosine 5'-phosphosulfate synthase 1 targeting cancer therapy.
    Alharbi B; Alharethi SH; Al-Soud WA; Ahmed Al-Keridis L; Aljohani AA; Jairajpuri DS; Alshammari N; Adnan M
    J Biomol Struct Dyn; 2024 Apr; 42(6):3193-3203. PubMed ID: 37184152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors.
    Gómez-Ganau S; Castillo J; Cervantes A; de Julián-Ortiz JV; Gozalbes R
    Curr Top Med Chem; 2020; 20(18):1628-1639. PubMed ID: 32493189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigation of molecular mechanism leading to gefitinib and osimertinib resistance against EGFR tyrosine kinase: molecular dynamics and binding free energy calculation.
    Singh A; Mishra A
    J Biomol Struct Dyn; 2023 Jul; 41(10):4534-4548. PubMed ID: 35510318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
    Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
    J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular screening reveals Variolin B as a multitargeted inhibitor of lung cancer: a molecular docking-based fingerprinting and molecular dynamics simulation study.
    Almasoudi HH; Mashraqi MM; Alshamrani S; Alsalmi O; Alharthi AA; Gharib AF
    J Biomol Struct Dyn; 2024; 42(1):11-21. PubMed ID: 37771142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-Based Drug Design Studies Toward the Discovery of Novel Chalcone Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors.
    Al-Anazi M; Al-Najjar BO; Khairuddean M
    Molecules; 2018 Dec; 23(12):. PubMed ID: 30563058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular dynamics simulation for screening phytochemicals as α-amylase inhibitors from medicinal plants.
    Sharma P; Joshi T; Joshi T; Chandra S; Tamta S
    J Biomol Struct Dyn; 2021 Oct; 39(17):6524-6538. PubMed ID: 32748738
    [No Abstract]   [Full Text] [Related]  

  • 38. Natural alkaloids targeting EGFR in non-small cell lung cancer: Molecular docking and ADMET predictions.
    Saini N; Grewal AS; Lather V; Gahlawat SK
    Chem Biol Interact; 2022 May; 358():109901. PubMed ID: 35341731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular docking of the pentapeptide derived from rice bran protein as anticancer agent inhibiting both receptor and non-receptor tyrosine kinases.
    Gasymov OK; Kecel-Gunduz S; Celik S; Akyuz S; Ozel AE; Agaeva G; Suleymanova LM; Agaeva U; Bakhishova M; Aliyev JA
    J Biomol Struct Dyn; 2023 Jul; 41(10):4321-4343. PubMed ID: 35477348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying novel therapeutic inhibitors to target FMS-like tyrosine kinase-3 (FLT3) against acute myeloid leukemia: a molecular docking, molecular dynamics, and DFT study.
    Islam MR; Osman OI; Hassan WMI
    J Biomol Struct Dyn; 2024; 42(1):82-100. PubMed ID: 36995071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.